How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells

被引：6

作者：

Nagler, Arnon ^{[1
]}

Perriello, Vincenzo Maria ^{[1
,2
,3
,4
]}

Falini, Lorenza ^{[1
,2
,3
,4
]}

Falini, Brunangelo ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Sheba Med Ctr, Div Hematol, Tel Hashomer, Israel

[2] Univ Perugia, Inst Hematol, Perugia, Italy

[3] Univ Perugia, Ctr Hematooncol Res, Perugia, Italy

[4] Santa Maria della Misericordia Hosp, Perugia, Italy

[5] Univ Perugia, Sect Hematol, Perugia, Italy

[6] Univ Perugia, Ctr Hematooncol Res CREO, Dept Med, Perugia, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期

关键词：

Chimeric antigen receptor (CAR) T cells; CD19; cytokine release syndrome (CRS); immune effector cell-associated neurotoxicity syndrome (ICANS); immunohistochemistry; lymphoma; monoclonal antibodies; TERM-FOLLOW-UP; AXICABTAGENE CILOLEUCEL; ALLOGENEIC TRANSPLANTATION; INFECTIOUS COMPLICATIONS; POLATUZUMAB VEDOTIN; DLBCL PATIENTS; LUNG-CANCER; SINGLE-ARM; FDG PET/CT; THERAPY;

D O I：

10.1111/bjh.18724

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chimeric antigen receptor (CAR) T cells targeting CD19 represent a promising salvage immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), offering similar to 40% of long-term responses. In everyday clinical practice, haematologists involved in CAR T cell treatment of patients with R/R DLBCL have to deal with diagnostically complex cases and difficult therapeutic choices. The availability of novel immunotherapeutic agents for R/R DLBCL and recent advances in understanding CAR T-cell failure mechanisms demand a rational approach to identify the best choice for bridging therapy and managing post-CAR T-cell therapy relapses. Moreover, positron emission tomography/computerised tomography may result in false-positive interpretation, highlighting the importance of post-treatment biopsy. In this review, we discuss all above issues, presenting four instructive cases, with the aim to provide criteria and new perspectives for CAR T-cell treatment of DLBCL.

引用

页码：396 / 410

页数：15

共 135 条

[51] G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma [J].

Galli, Eugenio ;

Allain, Vincent ;

Di Blasi, Roberta ;

Bernard, Sophie ;

Vercellino, Laetitia ;

Morin, Florence ;

Moatti, Hannah ;

Caillat-Zucman, Sophie ;

Chevret, Sylvie ;

Thieblemont, Catherine .

BONE MARROW TRANSPLANTATION, 2020, 55 (12) :2347-2349

[52] Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy [J].

Gardner, Rebecca ;

Wu, David ;

Cherian, Sindhu ;

Fang, Min ;

Hanafi, Laila-Aicha ;

Finney, Olivia ;

Smithers, Hannah ;

Jensen, Michael C. ;

Riddell, Stanley R. ;

Maloney, David G. ;

Turtle, Cameron J. .

BLOOD, 2016, 127 (20) :2406-2410

[53] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[54] Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial [J].

Guglielmi, C ;

Gomez, F ;

Philip, T ;

Hagenbeek, A ;

Martelli, M ;

Sebban, C ;

Milpied, N ;

Bron, D ;

Cahn, JY ;

Somers, R ;

Sonneveld, P ;

Gisselbrecht, C ;

Van der Lelie, H ;

Chauvin, F .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3264-3269

[55] Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis [J].

Hamadani, Mehdi ;

Gopal, Ajay K. ;

Pasquini, Marcelo ;

Kim, Soyoung ;

Qiu, Xianmiao ;

Ahmed, Sairah ;

Lazaryan, Aleksandr ;

Bhatt, Vijaya Raj ;

Daly, Andrew ;

Lulla, Premal ;

Ciurea, Stefan ;

Gauthier, Jordan ;

Agrawal, Vaibhav ;

Grover, Natalie S. ;

Lekakis, Lazaros ;

Modi, Dipenkumar ;

Dahi, Parastoo B. ;

Herr, Megan M. ;

Johnson, P. Connor ;

Hashmi, Hamza ;

Hematti, Peiman ;

Locke, Frederick L. .

BLOOD ADVANCES, 2022, 6 (02) :486-494

[56] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma [J].

Hamadani, Mehdi ;

Radford, John ;

Carlo-Stella, Carmelo ;

Caimi, Paolo F. ;

Reid, Erin ;

O'Connor, Owen A. ;

Feingold, Jay M. ;

Ardeshna, Kirit M. ;

Townsend, William ;

Solh, Melhem ;

Heffner, Leonard T. ;

Ungar, David ;

Wang, Luqiang ;

Boni, Joseph ;

Havenith, Karin ;

Qin, Yajuan ;

Kahl, Brad S. .

BLOOD, 2021, 137 (19) :2634-2645

[57] CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape [J].

Hamieh, Mohamad ;

Dobrin, Anton ;

Cabriolu, Annalisa ;

van der Stegen, Sjoukje J. C. ;

Giavridis, Theodoros ;

Mansilla-Soto, Jorge ;

Eyquem, Justin ;

Zhao, Zeguo ;

Whitlock, Benjamin M. ;

Miele, Matthew M. ;

Li, Zhuoning ;

Cunanan, Kristen M. ;

Huse, Morgan ;

Hendrickson, Ronald C. ;

Wang, Xiuyan ;

Riviere, Isabelle ;

Sadelain, Michel .

NATURE, 2019, 568 (7750) :112-+

[58] Primary nodal anthracosis identified by EBUS-TBNA as a cause of FDG PET/CT positive mediastinal lymphadenopathy [J].

Hewitt, Richard J. ;

Wright, Corrina ;

Adeboyeku, David ;

Ornadel, Dan ;

Berry, Matthew ;

Wickremasinghe, Melissa ;

Wright, Andrew ;

Sykes, Annemarie ;

Kon, Onn Min .

RESPIRATORY MEDICINE CASE REPORTS, 2013, 10 :48-52

[59] Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma [J].

Hill, Brian T. ;

Roberts, Zachary J. ;

Xue, Allen ;

Rossi, John M. ;

Smith, Mitchell R. .

BONE MARROW TRANSPLANTATION, 2020, 55 (06) :1184-1187

[60] Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy [J].

Hill, Joshua A. ;

Li, Daniel ;

Hay, Kevin A. ;

Green, Margaret L. ;

Cherian, Sindhu ;

Chen, Xueyan ;

Riddell, Stanley R. ;

Maloney, David G. ;

Boeckh, Michael ;

Turtle, Cameron J. .

BLOOD, 2018, 131 (01) :121-130

← 1 2 3 4 5 6 7 8 9 10 →